Condition
Ulcerative colitis news across medications, symptoms, monitoring, procedures, research, access, and daily life.
Page 22 of 40 · 1920 articles
A dedicated Crohn’s and Colitis Center can coordinate advanced diagnostics, medical and surgical care, nutrition, and mental-health support — all of which can improve symptom management and quality of life. It also...
The study tests a new mechanism (TL1A inhibition) that may reduce inflammation and fibrosis in IBD. Positive phase 2b results suggest duvakitug could become another treatment option if later trials confirm benefit and...
This article summarizes positive phase IIb trial results for duvakitug (anti‑TL1A) in moderate‑to‑severe Crohn’s disease and ulcerative colitis, which could lead to a new targeted treatment option if later phase trials...
A locally delivered rifamycin formulation reduced macroscopic and microscopic colonic damage in an acute rat model of colitis, suggesting a potential new local therapeutic approach worth further preclinical evaluation.
Based on the title and source metadata, this appears to be a clinical study related to Ulcerative colitis, Inflammatory bowel disease, and Research and clinical trials. The original article is from Journal of...
Depression is common in people with IBD and can worsen quality of life and disease outcomes. This trial explores whether mirtazapine—an antidepressant thought to have favorable gastrointestinal tolerability—can be...
Pouchitis is a common, sometimes chronic complication after IPAA surgery for ulcerative colitis and can substantially affect quality of life. If topical 5-ASA prevents pouchitis, it could offer a simple prophylactic...
This analysis suggests upadacitinib works and has a similar safety and pharmacokinetic profile in East Asian patients with moderately to severely active ulcerative colitis as in the global trials, which may reassure...
The study links NEAT1, a long noncoding RNA, to neutrophil-driven mucosal inflammation in ulcerative colitis and suggests NEAT1 affects neutrophil activity via glycolysis. That points to a new molecular pathway that...
A new molecular finding (PTPRK::RSPO3 fusion) in a serrated colorectal lesion from a person with ulcerative colitis may be relevant to understanding dysplasia and cancer pathways in IBD, and could prompt further study of...
Coexistence of ulcerative colitis and collagenous colitis is rare but can change diagnosis and management. Stool calprotectin and biopsies helped identify and monitor disease activity, and adjusting mesalazine coincided...
Using TDM to optimize vedolizumab could improve outcomes but may raise treatment costs; patients and clinicians should know cost-effectiveness depends heavily on drug price and local healthcare thresholds.
This Taiwanese multicenter real-world study reports high 52-week clinical response and remission rates, sustained one-year drug persistence, and meaningful fistula healing with ustekinumab in patients with Crohn’s...
Many women with UC use hormonal contraception and worry it might worsen disease activity. This study provides evidence that HCT was not linked to more recurrent flares or higher cumulative inflammatory burden in the...
Based on the title and source metadata, this appears to be a basic science related to Ulcerative colitis, Inflammatory bowel disease, and Research and clinical trials. The original article is from Journal of Functional...
CAR-based cellular therapies could offer a new way to reset immune responses in some forms of IBD, potentially helping patients who do not respond to existing biologics or small molecules.
An FDA approval for an autoinjector of a biosimilar ustekinumab can make treatment easier to administer and may increase availability or affordability of a drug used to treat Crohn’s disease and ulcerative colitis....
A new Phase 3 trial is testing ponesimod, an oral S1P-modulator, for moderately to severely active ulcerative colitis — this could expand oral treatment options if later shown effective and safe.
Diagnosis between UC, Crohn’s disease, and unclassified IBD can change in a meaningful minority of patients over years. Awareness of common reasons for reclassification (segmental disease, strictures) helps guide...
An FDA approval of an autoinjector for ustekinumab may make self‑injection easier and more convenient for people with Crohn’s disease or ulcerative colitis who use this biologic. Changes in delivery format can also...
New phase IIb trial results suggest an anti‑TL1A antibody (duvakitug) produced measurable benefit in both Crohn’s disease and ulcerative colitis, which could lead to a new treatment option if later phase III trials...
Mesalazine is commonly used in ulcerative colitis; recognizing rare but serious myocarditis linked to it can lead to rapid treatment changes and recovery. Distinguishing drug-induced myocarditis from IBD-related...
The study suggests a targeted microbiome-based drug (sialidase inhibitor) may protect the mucus barrier and improve symptoms in ulcerative colitis without the broad disruption caused by antibiotics, which could be...
People with ulcerative colitis taking etrasimod may have higher drug levels if they have certain CYP2C9 genotypes or significant liver impairment; dose adjustments could be needed to avoid increased exposure.
Patients with UC who fail both anti-TNF and JAK inhibitor therapies have limited options. This report suggests tacrolimus can be used as a short-term bridge or in combination to reach another maintenance drug, with many...
This study suggests a plant extract might boost ketone-body levels and reduce colitis-like inflammation in a mouse model — a concept that could inform future dietary or therapeutic research for ulcerative colitis but is...
The review explains why many patients still fail current therapies and summarizes promising new research directions (microRNA, microbiome therapies, stromal cell approaches) that could change treatment strategies.
The review highlights that colorectal IBD is under-recognized and often mistaken for infectious colitis in sub‑Saharan Africa due to limited diagnostic and specialist resources, which can delay appropriate care.
People with ulcerative colitis face a higher colorectal cancer risk driven in part by chronic inflammation; this review explains the molecular and immune mechanisms behind that risk and highlights biomarkers and...
The study links specific foods and combined dietary patterns with higher or lower odds of ulcerative colitis, which could inform patient conversations about diet and priorities for future research.
Compares widely used modelled GBD rates with population-based observations and finds they are not interchangeable for country-year estimates—important for research, surveillance, and policy that rely on these numbers.
Population estimates help patients understand how common IBD is and show that ulcerative colitis is more common than Crohn’s in this survey. Knowing prevalence and who is more likely to be diagnosed can help people feel...
Updated FDA prescribing information affects safety monitoring and counseling for people with ulcerative colitis who take mesalamine, including children meeting the weight threshold. The label highlights kidney monitoring...
Prednisone is a commonly used systemic steroid for short-term control of IBD flares; label updates affect dosing, warnings, and official approved uses that patients and clinicians rely on.
This label update restates safety information for ROWASA (a mesalamine rectal formulation) used for distal ulcerative colitis. Patients with IBD should be aware of potential serious hypersensitivity reactions, kidney and...
Synthetic, severity-controlled endoscopic images could help researchers train and test IBD imaging algorithms and augment scarce labeled datasets, which may accelerate development of tools that interpret endoscopy for...
This update is important because tofacitinib is a JAK inhibitor approved for adults with moderately to severely active ulcerative colitis after inadequate response to TNF blockers, and the label includes major safety...
This label update affects people with IBD because tofacitinib is an approved oral JAK inhibitor for moderately to severely active ulcerative colitis and the label highlights important safety risks (infections, mortality,...
This is an FDA drug-label record for ABRILADA (an adalimumab product). It confirms that ABRILADA is approved for treating moderately to severely active Crohn’s disease (adults and children 6+) and ulcerative colitis...
People with IBD (Crohn’s disease or ulcerative colitis) can develop vitamin K deficiency from malabsorption; this label clarifies that Vitamin K1 Injection is indicated for such situations and highlights important safety...
The FDA label defines who may be prescribed tofacitinib and highlights important safety warnings (serious infections, increased mortality signal, and malignancy risk) relevant to people with IBD and other autoimmune...
Preclinical research identified a plant-derived compound (polydatin) that may rebalance immune responses relevant to ulcerative colitis by targeting KEAP1–NFE2L2 signaling and reducing inflammatory T‑cell activity. This...
If validated, blood-based AI predictors of organ-specific aging might help flag organs aging faster in people with Crohn’s disease or other conditions, potentially enabling earlier monitoring or research into causes....
Recognizing eye inflammation as a possible early sign of IBD could shorten diagnostic delays and lead to earlier gastroenterology evaluation and treatment, which is especially important for children who often wait years...
This paper evaluates CAR, a simple blood‑based biomarker, in children with IBD and finds it reflects disease severity and changes over time in pediatric Crohn’s disease. That matters because reliable, easy-to-measure...
The paper reports a materials-based strategy to improve zinc delivery and bioavailability that reduced dose while preserving beneficial effects in a mouse colitis model—relevant because zinc supports intestinal health...
People with IBD and clinicians often face decisions about whether to stop biologics or small molecules before abdominal surgery.
The study tests whether fewer random biopsies are needed during surveillance colonoscopy with modern high-definition scopes — a question that could change how often biopsies are taken, affect procedure time, costs, and...
